Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.3% – Still a Buy?

Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTXGet Free Report) traded up 3.3% during trading on Friday . The stock traded as high as $11.60 and last traded at $11.32. 1,268,100 shares were traded during trading, an increase of 275% from the average session volume of 337,931 shares. The stock had previously closed at $10.96.

Silverback Therapeutics Trading Down 1.2 %

The firm has a market cap of $403.13 million, a price-to-earnings ratio of -4.62 and a beta of 0.60. The stock’s 50 day moving average is $14.25 and its 200 day moving average is $12.31.

Silverback Therapeutics Company Profile

(Get Free Report)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Featured Stories

Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.